コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 g atoms heavier than hydrogen was considered unreasonable.
2 nition that these symptoms are excessive and unreasonable.
3 ha]D 0 (c 0.50, CHCl3)]47 was biogenetically unreasonable.
4 al manipulations, show that these models are unreasonable.
5 so the missing-at-random assumption is often unreasonable.
6 o branch- and tree-length estimates that are unreasonable.
7 but are frequently dismissed as burdensome, unreasonable, and even counter to good-quality patient c
8 er than pathophysiology, were scientifically unreasonable; and that a "race-based" approval could be
9 e citric acid cycle on mineral surfaces make unreasonable assumptions about the catalytic properties
10 roduction of missing data mechanisms and the unreasonable assumptions that underlie CC and LOCF and r
11 we examine the key - but often biologically unreasonable - assumptions underlying this approach; for
12 cise quantification of ammonia, avoiding the unreasonable comparisons in photo/electrocatalytic ammon
14 alify for the Medicare pass-through program, unreasonable cost may have been a deterrent to their use
15 work, many thousands of patients, and wholly unreasonable delay in approval of a treatment whose effe
16 alignments were less stable and structurally unreasonable deletions were observed when matching again
17 imation of FDR and by the implicit use of an unreasonable estimator of the true proportion of equival
20 for clustering had limited impact, and only unreasonable levels of unmeasured confounding would have
23 e concerns are based on comparisons that are unreasonable or ignore the ecological context from which
25 n genes for targeted research, combined with unreasonable publication pressures and recent developmen
26 st for what healthcare providers believe are unreasonable requests, we believe more attention should
28 te risks for chemicals determined to pose an unreasonable risk to human health and the environment.
29 ronmental Protection Agency (USEPA) to be an unreasonable risk to human health in some occupational c
30 t or sustain human life or present potential unreasonable risk to patients, via the Premarket Approva
32 products are not exposed to significant and unreasonable risk, the FDA reviews medical and scientifi
33 icantly different during COVID-19, including unreasonable risks to self/family (26.7%, P < .001) and
34 on should be exercised to avoid excessive or unreasonable safety requirements, which may lead partici
37 of magnitude too small and argue that it is unreasonable to expect theoretical clarity based on such
39 the heterogeneity in reported effects, it is unreasonable to think that, in such circumstances, point
42 for the dissociation rate and undefined (or unreasonable) values for the stall force, at which V van
43 ectly experienced information is assigned an unreasonable weight and taken into account multiple time